# MapLight Therapeutics, Inc. (MPLT)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $30.11 (+8.33%)

> MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. Its primary focus is on discovering and advancing circuit-specific treatments designed to address severe and difficult-to-treat brain conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease. The company's leading drug candidate, ML-007C-MA, combines M1/M4 muscarinic agonism with a peripherally acting anticholinergic, specifically targeting symptoms of schizophrenia and Alzheimer’s disease-related psychosis. Additional candidates in the pipeline address social deficits in autism, motor issues in Parkinson’s disease, and agitation-related disorders through novel pharmacological approaches. Founded in 2018 by leaders in psychiatry and neuroscience, MapLight Therapeutics leverages a proprietary discovery platform that identifies and modulates neural circuits causally linked to disease, aiming to move beyond the limitations of traditional CNS medications. The company plays a significant role in the ongoing evolution of neuropsychiatric drug development, prioritizing scientific rigor and circuit specificity to potentially offer safer and more effective therapeutic options for underserved patient populations.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/MPLT)